Keywords: Novartis, Financial results, Second-quarter 2012, Sandoz, Alcon

Novartis beats forecasts, despite generic and currency hits

Article | 19 July 2012

Print This

Second-quarter 2012 group net sales at Swiss drug major Novartis (NOVN: VX) came in at of $14.3 billion, a rise of 1% at ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in